THANK YOU FOR SUBSCRIBING
A Cambridge, MA-based biotech firm, Akero Therapeutics, Inc., , finished a $65m Series A funding for treatment of non-alcoholic steatohepatitis (NASH) and different serious metabolic ailments.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The round was co-driven by Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures.
The organization plans to utilize the funds to propel its lead clinical program AKR-001.
Established by Apple Tree Partners Jonathan Young, Ph.D., J.D., President, and CEO, and Timothy Rolph, D.Phil., Chief Scientific Officer, Akero is progressing new pharmaceutical medicine to treat serious metabolic diseases by reestablishing the balance in metabolism.
The organization is creating AKR-001, a novel, long-acting fibroblast development factor 21 (FGF21) analogue, which was solely licensed from Amgen. It intends to start Phase 2 clinical studies of AKR-001 for the treatment of NASH and is assessing its capability to treat aditional serious metabolic diseases.
Check Out Review Of CIOReview : Crunchbase, Glassdoor
Check This Out : CIOReview Overview, Muckrack
More in News